DALLAS–(BUSINESS WIRE)–Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene remedy firm centered on growing and commercializing AAV-based gene therapies for the remedy of monogenic illnesses of the central nervous system in each uncommon and huge affected person populations, at this time introduced new additions to its management workforce with the appointments of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Company Communications and Investor Relations.
“We’re excited to welcome Greg and Kim to Taysha’s management workforce,” mentioned RA Session II, President, Founder and CEO of Taysha. “They every carry vital area expertise and their contributions can be invaluable as we proceed our mission of eradicating monogenic CNS illnesses. Greg’s technical experience in AAV gene remedy manufacturing alongside together with his confirmed success in developing a number of cGMP gene remedy services and Kim’s deep expertise throughout capital markets and company communications will add super worth to the workforce. Importantly, each share our unrelenting, patient-first focus and fervour for bringing new cures to life.”
Mr. Gara has over 25 years of expertise in designing, developing, and beginning up large- and small-scale manufacturing services for biotechnology corporations globally. Previous to becoming a member of Taysha, he served as Vice President of Pharmaceutical Engineering at Sarepta, the place he led and managed manufacturing operations for all gene remedy merchandise. Earlier than Sarepta, he served as Vice President of Technical Operations and Engineering at AveXis, a Novartis firm, the place he led the design, building, and startup of the Libertyville facility and the brand new services in Analysis Triangle Park and Colorado. Mr. Gara additionally led the workforce for the power enlargement in North Carolina and the renovation of the Colorado website. Previous to AveXis, he led the services and engineering group at Hospira previous to the corporate’s acquisition by Pfizer. Earlier than becoming a member of Hospira, he spent 15 years at Amgen, holding positions of accelerating duty, and was a part of the Cork, Eire, building challenge. Mr. Gara acquired a B.A. in Biology and Environmental Science from Augustana Faculty.
“Taysha’s dedication to the event and commercialization of doubtless transformative gene remedy therapies and its revolutionary and pioneering spirit is actually inspiring and I’m excited to contribute in a significant means,” mentioned Mr. Gara. “I stay up for taking part in an instrumental function within the firm’s progress and enlargement of its manufacturing capabilities.”
Dr. Lee joins Taysha with over 20 years of capital markets, strategic company finance, and communications expertise from prior roles as a biotech fairness analysis analyst on Wall Road and company technique, communications, and investor relations skilled. She most just lately served as Head of Company Technique and Investor Relations at Lexicon Prescribed drugs and beforehand as Vice President of Company Technique, Company Communications and Investor Relations at Raptor Prescribed drugs till its acquisition by Horizon Pharma. Previous to becoming a member of Raptor, Dr. Lee was a biotechnology sell-side analyst at funding banks, together with Jefferies and Wedbush Securities, protecting biotechnology corporations throughout all market capitalizations, a number of therapeutic areas, and modalities. Dr. Lee acquired a B.S. in Organic Sciences from Stanford College and a D.O. from Kirksville Faculty of Osteopathic Drugs.
“In lower than one 12 months, Taysha has made extraordinary progress in growing and funding its elegant platform and quickly advancing its product candidates for the betterment of sufferers and I’m thrilled and grateful to be part of this journey,” mentioned Dr. Lee. “I’m desperate to be taught from and work alongside this workforce of gene remedy consultants at this thrilling stage of our firm’s lifecycle and I stay up for making lasting contributions.”
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS illness. With a singular concentrate on growing healing medicines, we goal to quickly translate our therapies from bench to bedside. We’ve mixed our workforce’s confirmed expertise in gene remedy drug improvement and commercialization with the world-class UT Southwestern Gene Remedy Program to construct an in depth, AAV gene remedy pipeline centered on each uncommon and large-market indications. Collectively, we leverage our totally built-in platform—an engine for potential new cures—with a purpose of dramatically enhancing sufferers’ lives. Extra info is on the market at www.tayshagtx.com.